Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 3/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
| ▸ | MGLL | Q99685 | 6/20 | 0.36 |
| ▸ | FAAH | O00519 | 5/20 | 0.36 |
| ▸ | MGAM | O43451 | 2/20 | 0.36 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | SI | P14410 | 2/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | TDP2 | O95551 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL425750 | 0.92 | TRPV1 (0.38) | TRPV1MGLLFAAHMGAMAMY1A | |
| SCHEMBL427200 | 0.89 | NAMPT (0.45) | KCNMA1MGAMAMY1AGAASI | |
| SCHEMBL426089 | 0.83 | NAMPT (0.38) | MGLLFAAHMGAMAMY1AGAA | |
| SCHEMBL425578 | 0.80 | FAAH (0.47) | KCNMA1MGLLFAAHMGAMAMY1A | |
| SCHEMBL424689 | 0.80 | KCNMA1 (0.42) | KCNMA1MGLLFAAHMGAMAMY1A | |
| SCHEMBL424826 | 0.79 | HCAR3 (0.49) | HPGD | |
| SCHEMBL427962 | 0.78 | KCNMA1 (0.48) | KCNMA1MGLLFAAHMGAMAMY1A | |
| SCHEMBL424832 | 0.77 | HPGD (0.41) | KMT2AHPGD | |
| SCHEMBL7906239 | 0.77 | KCNMA1 (0.37) | KCNMA1MGLLFAAHGAAF2 | |
| SCHEMBL425937 | 0.76 | KCNMA1 (0.51) | KCNMA1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | FAAH, FAAH2, ASAH1 | KCNMA1 3175/4885TRPV1 165/4885MGLL 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.